Collaboration and acquisition tracking in the biosimilar market for vaccines player

Target competitors.
100+ hours
Secondary research.
5 years'
Period covered.
Data library created.


A leading global player in vaccines.


The client wanted a detailed understanding of collaborations and acquisition activities in the biosimilar domain. The client was particularly interested in understanding the technologies pertaining to related specific biologic modalities. SG Analytics was engaged to support the client by gathering, structuring, and reporting relevant industry data of the past 5 years. The research was focused on:
  • Target companies - Novartis incl. Sandoz, Pfizer, J&J, Roche, Merck & Co, GSK, AstraZeneca, AbbVie, Amgen, Lilly, Novo Nordisk, Bayer, BMS, Boehringer Ingelheim, Biogen, Celgene
  • Investment focus – R&D and Manufacturing


SG Analytics performed an extensive secondary research to build a data library consisting of relevant deals including licensing agreements, acquisitions, and partnering initiatives of companies. The final report presented the following information:
  • A comprehensive list of deals in biosimilar domain.
  • Relevant trends of deals for specific biologic modalities.
  • Detailed information on type and amount of capital investment.
  • Quantitative analysis of deals and understanding the intention of deals.
  • Final recommendation based on our analysis.


SG Analytics provided a complete key collaborations analysis report to the client.
The report's holistic and accurate information helped identify the most promising biosimilar candidate in the market.